Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1

Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-S...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaddady, Pavan, Kandala, Bhargava, Yee, Ka Lai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577165/
https://www.ncbi.nlm.nih.gov/pubmed/32868326
http://dx.doi.org/10.1128/AAC.00590-20
_version_ 1783598148841635840
author Vaddady, Pavan
Kandala, Bhargava
Yee, Ka Lai
author_facet Vaddady, Pavan
Kandala, Bhargava
Yee, Ka Lai
author_sort Vaddady, Pavan
collection PubMed
description Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual post hoc PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen (This study has been registered at ClinicalTrials.gov under ClinicalTrials registration no. NCT02397096.)
format Online
Article
Text
id pubmed-7577165
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-75771652020-10-30 Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1 Vaddady, Pavan Kandala, Bhargava Yee, Ka Lai Antimicrob Agents Chemother Antiviral Agents Doravirine is a non-nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus type 1 (HIV-1) infection. A population pharmacokinetic (PK) model for treatment-naive participants in doravirine clinical studies was updated with data from switch participants in the DRIVE-SHIFT trial and used to estimate individual post hoc PK parameter values and evaluate the efficacy exposure-response relationship. The results support the 100-mg dose for people living with HIV switching to a doravirine-based regimen (This study has been registered at ClinicalTrials.gov under ClinicalTrials registration no. NCT02397096.) American Society for Microbiology 2020-10-20 /pmc/articles/PMC7577165/ /pubmed/32868326 http://dx.doi.org/10.1128/AAC.00590-20 Text en Copyright © 2020 Vaddady et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Antiviral Agents
Vaddady, Pavan
Kandala, Bhargava
Yee, Ka Lai
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
title Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
title_full Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
title_fullStr Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
title_full_unstemmed Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
title_short Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1
title_sort population pharmacokinetic and pharmacodynamic analysis to evaluate a switch to doravirine/lamivudine/tenofovir disoproxil fumarate in people living with hiv-1
topic Antiviral Agents
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577165/
https://www.ncbi.nlm.nih.gov/pubmed/32868326
http://dx.doi.org/10.1128/AAC.00590-20
work_keys_str_mv AT vaddadypavan populationpharmacokineticandpharmacodynamicanalysistoevaluateaswitchtodoravirinelamivudinetenofovirdisoproxilfumarateinpeoplelivingwithhiv1
AT kandalabhargava populationpharmacokineticandpharmacodynamicanalysistoevaluateaswitchtodoravirinelamivudinetenofovirdisoproxilfumarateinpeoplelivingwithhiv1
AT yeekalai populationpharmacokineticandpharmacodynamicanalysistoevaluateaswitchtodoravirinelamivudinetenofovirdisoproxilfumarateinpeoplelivingwithhiv1

Ejemplares similares